Month: January 2017

Quantum Blue® Infliximab Assay Highlights

US: BÜHLMANN Quantum Blue® Infliximab is for Research Use Only in the US. Not to be used in diagnostic procedures. Canada: BÜHLMANN Quantum Blue® Infliximab: Health Canada License: 98838 Simple, Fast, Accurate Quantitative Results BÜHLMANN’s Quantum Blue® Product line is designed with an innovative solution based on established lateral flow technology which utilizes highly specific monoclonal antibodies to capture
Continue Reading

BÜHLMANN fCAL® turbo Calprotectin Assay Highlights

BÜHLMANN fCAL® turbo is for Research Use Only. Not to be used in diagnostic procedures. Health Canada License: 96808 Unique in Speed, Quality, Flexibility BÜHLMANN fCAL® turbo the turbidimetric immunoassay, is a flexible solution to be applied on most clinical chemistry analyzers. The technology implements a further milestone in fecal calprotectin quantification. It offers significant advantages over
Continue Reading

Connect with BUHLMANN Diagnostics Corp at CDDW 2017

Canadian Digestive Diseases Week (CDDW) 2017 BUHLMANN Diagnostics Corp Booth: #1032 Mar 03 – 06, 2017 LOCATION The Fairmont Banff Springs Banff, Alberta LEARN MORE Click & Contact CDDW 2017 BUHLMANN Team Connect with our team ahead of time, learn more about our Calprotectin Assays or schedule a meeting! COLLIN SHAW VP of Business Development
Continue Reading

Integration of Controls into BUHMANN Quantum Blue® Assays

Quantum Blue® Lateral Flow Assays: Simple, Fast, Accurate Quantitative Results Now Even More Convenient with 2 Lot Specific Ready-to-use Controls! Available NOW with Integrated Controls: Quantum Blue® Infliximab Assay The BÜHLMANN Quantum Blue® Infliximab is the ONLY  quantitative rapid test in the market for infliximab that can provide fast, reliable information for infliximab.  The test is designed for the selective
Continue Reading

Post with new Category Testing

3 Reasons to Consider this Method in Kinase Inhibitor Drug Development Basophils are the circulating immune cells of allergy that share many of the signaling pathways that are also present in other immune cells and are responsible for diseases such as cancer and autoimmune disorders. Several drug development projects are focusing on inhibition of these
Continue Reading
Sign Up for BUHLMANN Updates!

Enter your email and stay on top of things,